Skip to content
Company Analysis

Amarin Corporation plc AMRN

A comprehensive view of key metrics, scores, and financial health for Amarin Corporation plc

Overview of Amarin Corporation plc

AMRN NCM
Healthcare Drug Manufacturers - General Small Cap
Amarin Corporation plc (AMRN), is a Small Cap company, in the Drug Manufacturers - General industry, last closed at $15.34, about 2.7% undervalued vs fair value, +82.6% 1Y return, ranked 1060/1110 in sector.
$15.34
-6.29%
As of March 13, 2026
Previous close • Vol 90d: 55.2%
52-Week Range
Market Cap
$319.13M
Enterprise Value
$203.06M
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Amarin Corporation plc.

Top Beats

Quick Facts

Website https://www.amarincorp.com
HQ Dublin
Employees 275
Fiscal year Dec 31

Next Events

Earnings May 6 Estimated

Fair Value Snapshot

Bear Base Bull
$14
$16
$18
Current: $15.34 +3% vs base

Engine Room Money Flow™

Small Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$182.8M
-20.1%%
Gross Profit
$120.9M
48.5%%
R&D Expense
$19.8M
-5.1%%
Operating Income (EBIT)
$-77.2M
-43.9%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

R&D Intensity
10.8%
Fair

Lower R&D intensity - may indicate mature portfolio or cost cuts

Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$2.0M

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
1/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Amarin Corporation plc's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
22
/100
Weak
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
14
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 85% Coverage
Trade-Off Triangle Visualization A ternary plot showing AMRN's balance between Growth (16.7%), Profitability (20.6%), and Safety (62.7%). Growth 17% Safety 63% Profitability 21%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

10th percentile vs peers
11
Key Signals
EPS Growth YoY -37.9% 26p Rev Growth YoY -20.1% 5p Revenue CAGR 3Y -20.9% 5p
Strengths
  • Current Ratio in top 20% of peers (3.31, 90th percentile)
  • Quick Ratio in top 20% of peers (2.39, 90th percentile)
  • Strong liquidity position vs peers
Risks
  • Growth in bottom 20% of peers (percentile: 10)
  • Rev Growth Yoy in bottom 20% of peers (-20.1%)

Profitability

13th percentile vs peers
13
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

40th percentile vs peers
41
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Amarin Corporation plc.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$15.75
- - -
+2.7% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info